Rhumbline Advisers Summit Therapeutics Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 122,394 shares of SMMT stock, worth $2.78 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
122,394
Previous 131,760
7.11%
Holding current value
$2.78 Million
Previous $2.54 Million
2.48%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding SMMT
# of Institutions
262Shares Held
90.3MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$766 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$197 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$179 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$91.3 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$88.7 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.57B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...